The Clinical Research Unit (CRU) at the Montreal Neurological Institute and Hospital (MNI/H) began as part of the Multiple Sclerosis Clinic under the direction of Dr. Gordon Francis in 1986. The CRU was involved with the first MS clinical trials that eventually led to the approved injectable treatments in use today and that have changed the course of treatment for patients living with MS. Today, under the direction of Dr. Angela Genge, the CRU continues to be involved in pivotal MS trials, and has expanded into many more neurological disease areas. Our goal is to help contribute to the development of more effective therapies for neurological diseases.
The CRU takes part in clinical trials for all major neurological disorders such as Amyotrophic Lateral Sclerosis (ALS), , Parkinson’s Disease, and Alzheimer’s Disease. With our diverse patient population at the MNI/H, we specialize in conducting trials for rare neurological conditions including, but not limited to, diseases of the spine, muscular dystrophies and other neuromuscular diseases, brain cancer, and movement disorders. We work closely with the staff and patients at the Neuro, raising awareness about clinical trials and giving patients and their caregivers the opportunity to be involved in the latest research for better therapies. The CRU also takes part in the Open Science Initiative, actively participating in the C-BIG project to help build and expand the repository of biological specimens and clinical information from patients with neurological diseases. This platform allows patients to contribute to advancing our understanding of the diseases affecting them.
The CRU is located on the second floor of the Montreal Neurological Institute, in suite 207. We are a team of dedicated staff involved in over 100 clinical trials, and working in collaboration with the Experimental Therapeutics Program and the McConnell Brain Imaging Centre on various research initiatives.
If you or your loved one are suffering from a neurological disease and would like more information on opportunities for involvement in research, please contact the CRU Manager Maxime Boutin-Caron at: email@example.com.